WALTHAM, Mass. and BOULDER, Colo., June 11, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced it has secured a debt financing facility of up to $400 million with credit funds managed by SLR Capital Partners, LLC ("SLR"). An initial tranche of$50 million was drawn at closing, with future tranches available based on the achievement of key clinical and commercial milestones align ...